New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
08:37 EDTKERXKeryx announces EMA validation of MAA for Zerenex
Keryx Biopharmaceuticals announced that the European Medicines Agency, or EMA, has determined that the company's Marketing Authorization Application, or MAA, seeking the approval of Zerenex as a treatment for hyperphosphatemia in patients with chronic kidney disease, CKD, including dialysis- and non-dialysis-dependent CKD, is valid. Validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. The EMA's review of the application will follow the centralized marketing authorization procedure. If approved by the EMA, Zerenex will receive marketing authorization in all 27 member states of the European Union, as well as in Norway, Liechtenstein and Iceland.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
11:10 EDTKERXKeryx management to meet with Oppenheimer
Subscribe for More Information
October 17, 2014
14:41 EDTKERXKeryx down 4.4% to $15.31, Orange Book cited
Shares of Keryx are lower in afternoon trading after no NCE decision in the Orange Book was updated today, as pointed out by TheStreet's Adam Feuerstein earlier on Twitter.
October 8, 2014
10:58 EDTKERXKeryx management to meet with Brean Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use